Zemplar and Failure to thrive - a phase IV clinical study of FDA data

Summary:

Failure to thrive is reported as a side effect among people who take Zemplar (paricalcitol), especially for people who are male, 60+ old, also take Tylenol, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Failure to thrive when taking Zemplar. It is created by eHealthMe based on reports of 15,456 people who have side effects when taking Zemplar from the FDA, and is updated regularly.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.

What is Failure to thrive?

Failure to thrive (inadequate weight gain and physical growth in children) is found to be associated with 772 drugs and 1,167 conditions by eHealthMe. Check the latest studies of Failure to thrive.

On Jul, 14, 2026

15,456 people reported to have side effects when taking Zemplar.
Among them, 16 people (0.1%) have Failure to thrive.

Among these 16 people:

What is the gender of people who have Failure to thrive when taking Zemplar? *

female: 37.5 %
male: 62.5 %

What is the age of people who have Failure to thrive when taking Zemplar? *

What are other drugs people take besides Zemplar? *

What are other side effects people have besides Failure to thrive? *

Weakness: 7 people, 43.75%
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking): 5 people, 31.25%
Peritonitis Bacterial (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs by bacterial): 4 people, 25.00%
Device Related Infection: 4 people, 25.00%
Acute Myocardial Infarction (acute heart attack): 4 people, 25.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 25.00%
Pulmonary Oedema (fluid accumulation in the lungs): 4 people, 25.00%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 3 people, 18.75%
Pancreatitis Acute (sudden inflammation of pancreas): 3 people, 18.75%
Pancreatic Pseudocyst (collection of tissue and fluids that forms on pancreas): 3 people, 18.75%

What are the existing conditions these people have? *

Fever: 2 people, 12.50%
Bacteraemia (presence of bacteria in the blood): 2 people, 12.50%
High Blood Pressure: 2 people, 12.50%
High Blood Cholesterol: 2 people, 12.50%
Chronic Renal Failure (kidney failure): 2 people, 12.50%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 12.50%
Renal Disorder (kidney disease): 1 person, 6.25%
Blood Parathyroid Hormone Increased: 1 person, 6.25%
Blood Phosphorus Increased: 1 person, 6.25%
Cardiac Failure Congestive: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Zemplar and have Failure to thrive?

- Check whether Failure to thrive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zemplar:

Zemplar (15,494 reports)

Browse all side effects of Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Failure to thrive:

Failure to thrive (772 drugs)

Browse all the conditions that are associated with Failure to thrive:

Failure to thrive (1,167 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paricalcitol (the active ingredients of Zemplar) and Zemplar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.